Gastroparesis Market Expected to rise, 2034 | Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, expected to drive market

The Gastroparesis market growth is driven by factors like increase in the prevalence of Gastroparesis, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Gastroparesis market report [https://www.delveinsight.com/report-store/gastroparesis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Gastroparesis market size, share, Gastroparesis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Gastroparesis market size growth forward.

Some of the key highlights from the Gastroparesis Market Insights Report:

*
Several key pharmaceutical companies, including Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, and others, are developing novel products to improve the Gastroparesis treatment outlook.

*
In December 2024, Evoke Pharma, a specialty pharmaceutical company focused on gastrointestinal (GI) treatments, highlighted its dedication to supporting patients and healthcare providers managing gastroparesis, especially following the FDA's recent update on the domperidone supply. As the only FDA-approved nasal spray for treating acute and recurrent diabetic gastroparesis in adults, GIMOTI Registered (metoclopramide) is well-positioned to meet the ongoing needs of patients struggling with other treatment options.

*
In September 2024, the US Food and Drug Administration (FDA) rejected the new drug application (NDA) submitted by Vanda Pharmaceuticals for tradipitant as a treatment for gastroparesis symptoms.

*
Several leading companies in the Gastroparesis field, including Evoke Pharma, ANI Pharmaceuticals, CinDome Pharma, Neurogastrx, RaQualia Pharma, and others, are actively developing treatments for the condition. In 2023, the total Gastroparesis market size across the 7MM was approximately USD 240 million, with moderate growth expected at a CAGR through 2034. The United States held the largest share of the market, accounting for around 80% of the total market size in the 7MM in 2023, with continued growth anticipated.

*
Among emerging therapies for Gastroparesis, PCS12852 and tradipitant are expected to have the most significant impact on the market size across the 7MM. The introduction of PCS12852, a selective 5-HT4 agonist, is projected to significantly reshape the Gastroparesis treatment landscape and could become a market leader, potentially reaching a market size of over USD 100 million by 2034.

*
In 2023, the total market size for Gastroparesis in the 7MM was approximately USD 240 million and is expected to grow at a moderate compound annual growth rate (CAGR) by 2034. Gastroparesis, meaning "stomach paralysis," is a digestive disorder marked by delayed gastric emptying of solid food without any mechanical obstruction. Common symptoms include early satiety, postprandial fullness, nausea, vomiting, belching, and bloating. Many patients with Gastroparesis also experience mood disorders, with about half suffering from anxiety and 38% dealing with depression.

*
Gastroparesis can be idiopathic or linked to conditions such as diabetes, surgical interventions (iatrogenic or postsurgical), neurological disorders, or infections like Salmonella gastroenteritis. The primary causes of Gastroparesis include diabetes, postsurgical factors, iatrogenic causes, and idiopathic origins. Based on these causes, the condition is categorized into three main types: idiopathic, diabetic, and postsurgical gastroparesis.

*
Diagnosis is typically confirmed through gastric emptying tests, though gastric motility assessments often don't correlate well with symptoms or quality of life in patients. Other diagnostic tools include scintigraphy, wireless motility capsules (WMC), and carbon breath testing, with scintigraphic gastric emptying being the gold standard.

*
Several medications approved for other conditions, such as nortriptyline, mirtazapine, and buspirone, are used off-label to treat gastroparesis symptoms. However, there are no approved gastroparesis-specific drugs in the EU4 and the UK, leading to a heavy reliance on drugs like domperidone for managing symptoms like nausea and vomiting.

*
Gastroparesis predominantly affects women, with approximately 70% of diagnosed cases being female and around 30% male. Among the 7MM, the United States has the highest number of prevalent cases of gastroparesis-like symptoms, with an estimated 4 million cases in 2023.

*
If dietary adjustments for gastroparesis do not alleviate symptoms, patients may be treated with prokinetic and antiemetic medications. Prokinetic drugs, such as metoclopramide, domperidone, and erythromycin, help enhance stomach contractions and improve gastric emptying. Metoclopramide is the only FDA-approved treatment for gastroparesis in the U.S. and remains a commonly chosen therapy. Additionally, several promising new prokinetic agents, like relamorelin, are in clinical trials. Relamorelin, a ghrelin receptor agonist, stimulates gastric contractions and has shown in Phase II studies to enhance gastric emptying and reduce gastroparesis symptoms.

*
As per DelveInsight analysis, the Gastroparesis market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Gastroparesis Market Landscape [https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Gastroparesis Overview

Gastroparesis, or "stomach paralysis," is a digestive disorder marked by delayed gastric emptying of solid food without any mechanical obstruction. Key symptoms include early satiety, postprandial fullness, nausea, vomiting, belching, and bloating. It is considered part of a broader group of gastric neuromuscular dysfunctions, which also involves impaired gastric accommodation. Diagnosing gastroparesis can be challenging due to symptom overlap with other conditions like functional dyspepsia.

Patients with upper abdominal symptoms such as nausea, vomiting, fullness, bloating, and epigastric pain may undergo gastric motility tests. An upper GI endoscopy is typically the first step, and if it doesn't identify the cause, motility and functional tests are conducted. The primary test for gastric motility is gastric emptying measurement, typically performed with scintigraphy over at least three hours, though the stable isotope breath test is the only one approved by regulatory agencies. These tests are well-established, with data from healthy controls available for comparison.

Do you know the treatment paradigms for different countries? Download our Gastroparesis Market Sample Report [https://www.delveinsight.com/report-store/gastroparesis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Gastroparesis Epidemiology Insights

*
In 2023, the United States had the highest number of prevalent cases of gastroparesis-like symptoms among the 7MM, with an estimated 4.5 million cases. In the EU4 and the UK, Italy had the largest number of diagnosed prevalent cases of gastroparesis, followed by Germany and France.

Gastroparesis Epidemiology Segmentation

DelveInsight's Gastroparesis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Gastroparesis historical patient pools and forecasted Gastroparesis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Gastroparesis Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

*
Gastroparesis Prevalence

*
Age-Specific Gastroparesis Prevalence

*
Gender-Specific Gastroparesis Prevalence

*
Diagnosed and Treatable Cases of Gastroparesis

Visit for more @ Gastroparesis Epidemiological Insights [https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Gastroparesis Market Outlook

Gastroparesis is a complex and debilitating condition with difficult-to-manage symptoms. The limited effectiveness and serious side effects of current treatments highlight the need for better options. The main goals of treatment are symptom management, addressing nutritional deficiencies, maintaining optimal weight, and treating underlying causes like diabetes or medications when possible. However, improving gastric emptying does not always alleviate symptoms.

Treatment typically starts with nutritional assessment and dietary changes, and if these aren't sufficient, pharmacological options are explored. Prokinetic drugs such as metoclopramide, domperidone, and erythromycin are used to speed up gastric emptying and reduce symptoms. Other drugs, including anti-emetics and psychotropic agents, may also be tried, though their effectiveness remains unproven. If medications fail, alternative treatments like endoscopy, electrical stimulation, or surgery may be considered.

With several potential therapies under investigation, it is expected that the treatment landscape for gastroparesis will undergo significant changes between 2024 and 2034.

Gastroparesis Marketed Drugs

*
GIMOTI (metoclopramide) Nasal Spray: Evoke Pharma

Gastroparesis Emerging Drugs

*
VLY-686 (tradipitant): Vanda Pharmaceuticals

*
CIN-102 (deudomperidone): CinDome Pharma

Gastroparesis Key Companies

*
Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, and others

For more information, visit Gastroparesis Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/gastroparesis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Gastroparesis Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Gastroparesis, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Gastroparesis epidemiology in the 7MM

*
Gastroparesis marketed and emerging therapies

*
Gastroparesis companies

*
Gastroparesis market drivers and barriers

Table of Contents:

1 Gastroparesis Market Key Comprehensive Insights

2 Gastroparesis Market Report Introduction

3 Competitive Intelligence Analysis for Gastroparesis

4 Gastroparesis Market Analysis Overview at a Glance

5 Executive Summary of Gastroparesis

6 Gastroparesis Epidemiology and Market Methodology

7 Gastroparesis Epidemiology and Patient Population

8 Gastroparesis Patient Journey

9 Gastroparesis Treatment Algorithm, Gastroparesis Current Treatment, and Medical Practices

10 Key Endpoints in Gastroparesis Clinical Trials

11 Gastroparesis Marketed Therapies

12 Gastroparesis Emerging Therapies

13 Gastroparesis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Gastroparesis

16 Gastroparesis Market Key Opinion Leaders Reviews

18 Gastroparesis Market Drivers

19 Gastroparesis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Gastroparesis Epidemiology 2034

DelveInsight's "Gastroparesis - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Gastroparesis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Gastroparesis Pipeline 2024

"Gastroparesis Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Gastroparesis market. A detailed picture of the Gastroparesis pipeline landscape is provided, which includes the disease overview and Gastroparesis treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gastroparesis-market-expected-to-rise-2034-vanda-pharmaceuticals-processa-pharmaceuticals-neurogastrx-cindome-pharma-expected-to-drive-market]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.